These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 22273313)

  • 1. Platelet function after cessation of chronic clopidogrel therapy.
    Perakis PG; Yunus T; Long G; Cheema ZF; Hammond R; Shanley CJ
    Am Surg; 2012 Jan; 78(1):51-6. PubMed ID: 22273313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
    Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers.
    Price MJ; Teirstein PS
    Am J Cardiol; 2008 Sep; 102(6):790-5. PubMed ID: 18774008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring.
    Metzler H; Prüller F; Münch A; Primus G; Kainz J; Hödl R; Rehak P
    Eur J Anaesthesiol; 2010 Feb; 27(2):138-45. PubMed ID: 19593147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity.
    Capranzano P; Tamburino C; Capodanno D; Miccichè E; D'Urso L; Calvi V; Angiolillo DJ; Tamburino C
    Thromb Haemost; 2011 Dec; 106(6):1149-57. PubMed ID: 22011914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
    Jakubowski JA; Payne CD; Li YG; Brandt JT; Small DS; Farid NA; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Feb; 99(2):409-15. PubMed ID: 18278193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):532-9. PubMed ID: 20729752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal timing of clopidogrel discontinuation in Japanese patients: platelet aggregation test using the VerifyNow® system.
    Takiuchi H; Tanemoto K
    Gen Thorac Cardiovasc Surg; 2015 Nov; 63(11):601-6. PubMed ID: 26298730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition.
    Lordkipanidzé M; Pharand C; Nguyen TA; Schampaert E; Diodati JG
    Ther Drug Monit; 2008 Jun; 30(3):372-8. PubMed ID: 18520610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug.
    Labarthe B; Théroux P; Angioï M; Ghitescu M
    J Am Coll Cardiol; 2005 Aug; 46(4):638-45. PubMed ID: 16098428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
    Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
    Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention.
    Muller O; Hamilos M; Bartunek J; Ulrichts H; Mangiacapra F; Holz JB; Ntalianis A; Trana C; Dierickx K; Vercruysse K; De Bruyne B; Wijns W; Barbato E
    Am J Cardiol; 2010 Feb; 105(3):333-8. PubMed ID: 20102944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions.
    Rudez G; Bouman HJ; van Werkum JW; Leebeek FW; Kruit A; Ruven HJ; ten Berg JM; de Maat MP; Hackeng CM
    Circ Cardiovasc Genet; 2009 Oct; 2(5):515-21. PubMed ID: 20031628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease.
    Jagroop IA; Matsagas MI; Geroulakos G; Mikhailidis DP
    Platelets; 2004 Mar; 15(2):117-25. PubMed ID: 15154604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers.
    Price MJ; Coleman JL; Steinhubl SR; Wong GB; Cannon CP; Teirstein PS
    Am J Cardiol; 2006 Sep; 98(5):681-4. PubMed ID: 16923461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
    Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L
    J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H; Lask S; Engelhardt A; Mügge A
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment.
    Angiolillo DJ; Costa MA; Shoemaker SB; Desai B; Bernardo E; Suzuki Y; Charlton RK; Zenni MM; Guzman LA; Bass TA
    Am J Cardiol; 2008 Feb; 101(4):440-5. PubMed ID: 18312754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of antiplatelet inhibition during neurointerventional procedures: the effect of antithrombotic duration and loading dose.
    Pandya DJ; Fitzsimmons BF; Wolfe TJ; Hussain SI; Lynch JR; Ortega-Gutierrez S; Zaidat OO
    J Neuroimaging; 2010 Jan; 20(1):64-9. PubMed ID: 19018951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.